Hikma Pharmaceuticals PLC
$22.280.0%1Y-7.0%
Mentions · last 7 days
0
Price updated 13h ago·X counts updated 1d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $HKMPF, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $HKMPF.
Drug Manufacturers - Specialty & Generic
No material change from last week — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate..
Top industry ETF
$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+50.5%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
0.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
10.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
16.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
4.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
1.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
15.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
41.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$1.26$1.10+14.5%
Q4 2025Feb 26, 2026$1.08$1.080.0%
Q2 2025Aug 7, 2025$1.07$1.22-12.3%
Q4 2024Feb 26, 2025$0.60——
Next earningsThu, Feb 25·consensus EPS $1.13
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$1.7B+17.5%39.6%18.0%$0.75$101.7M
Q2 FY25$1.7B+16.2%43.7%15.6%$1.08$93.0M
Q4 FY24$1.6B+19.5%42.3%16.8%$0.60$270.0M
Q2 FY24$1.6B+29.3%48.2%22.4%$1.02$129.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$3.5B$3.4B – $3.5B$2.21$2.18 – $2.2410
FY27$3.6B$3.5B – $3.6B$2.43$2.39 – $2.4610
FY28$3.8B$3.7B – $3.8B$2.62$2.58 – $2.654
FY29$3.9B$3.9B – $4.0B$2.71$2.67 – $2.755
FY30$4.1B$4.0B – $4.1B$3.15$3.10 – $3.195
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.66%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+11.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
β0.655-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.ListedOTCListed on an over-the-counter market (PNK / OTCQB / OTCQX), not a major exchange. Lower disclosure requirements and thinner liquidity.
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Citi sees Hikma discount as unwarranted after upgrade to forecastsHikma boost as broker raises price targetHikma jumps 10% as brokers point to profit beat and undemanding ratingHikma jumps 10% as brokers point to profit beat and undemanding ratingHikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
More in Drug Manufacturers - Specialty & Generic
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $HKMPF on X in the last 7 days.